A pilot study of natural interferon γ therapy for chronic hepatitis C

International Hepatology Communications

Volumn 6, Issue 5, 1997, Pages 264-273

  Sata, Michio ^a   Nakano, Hitoshi ^a   Ide, Tatsuya ^a   Sato, Taiji ^b   Matsukuma, Norito ^b   Suzuki, Hiroshi ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Social Insurance Kurume Daiichi Hospital   (Japan)

Author keywords

chronic hepatitis C; hepatitis C virus; interferon ; interferon therapy

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; GAMMA INTERFERON; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0031080566     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(97)00356-3     Document Type: Article

References (28)

1. [1] Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, nonB hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315: 1575-1578.
2. [2] Matsumoto A, Tanaka E, Suzuki T, et al. Viral and host factors that contribute to efficacy of interferon-α 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1273-1280.
3. [3] Omata M, Ito Y, Yokosuka O, et al. Randomized, double-blind, placebocontrolled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991; 36: 1217-1222.
4. [4] De Alavacate E, Camps J, Parclo Mindean J, et al. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alpha interferon. Liver 1993; 13: 73-79.
5. [5] Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
6. [6] Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β. Hepatology 1993; 18: 1319-1325.
7. [7] Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121-1130.
8. [8] Enomoto S, Sakuma I, Asahina Y, et al. Comparison of full-length sequence of interferon-sensitive and resistant hepatitis C virus Ib. Sensitivity to interferon is conferred by amino acid substitutions in the NSSA region. J Clin Invest 1995; 96: 224-230.
9. [9] Reichard O, Foberg U, Frydén A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994; 19: 280-285.
10. [10] Saracco G, Rosina F, Corena M, et al. Long-term follow up of patients with chronic hepatitis C treated with different doses of interferon-α 2b. Hepatology 1993; 18: 1300-1305.
11. [11] Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
12. [12] Brillianti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.
13. [13] Angelido M, Gandin C, Pescarmona E, et al. Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90: 263-269.
14. [14] Cerny A, McHutchison JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521-530.
15. [15] Shirai M, Okada M, Nishioka M, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994; 68: 3334-3342.
16. [16] Ferrari C, Valli A, Galanti L, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infection. Hepatology 1994; 19: 286-295.
17. [17] Liaw YF, Lee CS, Tsai SL, et al. T-cell mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368-1373.
18. [18] Koziel MJ, Dudley D, Afdhal N, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 7522-7532.
19. [19] Ando S, Ohta T, Tanimoto T, et al. Natural interferon-γ derived from lipopolysaccharide stimulated human myelo-monocytic HBL-38 cells. Jpn J Cancer Res (Gann) 1988; 79: 757-765.
20. [20] Franco A, Barnabe V, Natali P, et al. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8: 449-454.
21. 2-microglobulin by hepatocytes. Eur J Clin Invest 1988; 18: 343-351.
22. [22] Kato N, Yokosuka O, Hosoda K, et al. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus advanced liver disease. Hepatology 1993; 18: 16-20.
23. [23] Miyajima I, Sata M, Ide I, et al. Sequential interferon-α and β treatment in patients with chronic hepatitis C. J Jpn A Infect Dis 1996; 70: 690-695.
24. [24] Bisceglie AMD, Rustgi VK, Kassiamdes C, et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990; 11: 266-270.
25. [25] Carrenò V, Moreno A, Galiana F, et al. α- and γ-interferon versus α interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 1993; 17: 321-325.
26. [26] Sata M, Matsushima T, Kakumu S, et al. Clinical evaluation of intramuscular administration of natural interferon-γ in the treatment of chronic hepatitis B. Kurume Med J 1995; 42: 9-20.
27. 2-microglobulin. Proc Natl Acad Sci USA 1974; 1: 35-39.
28. [28] Toyonaga T, Hino O, Sugai S, et al. Chronic active hepatitis in transgenic mice expressing interferon-γ in the liver. Proc Natl Acad Sci USA 1994; 91: 614-618.